FLT3 and acute myeloid leukemia: Furthermore, our data lay further credence to the use of HiDAC/MITO as a chemotherapy backbone in innovative clinical trials incorporating novel agents such as the phase III trial assessing in older patients with R/R AML the combination of HiDAC/MITO and CPI-613, a mitochondrial tricarboxylic acid cycle inhibitor (NCT03504410) which has shown promising activity in a phase 1 study [52] or in combination with the FLT3 inhibitors quizartinib and crenolanib (NCT03250338 and NCT03250338, respectively).